https://scholars.lib.ntu.edu.tw/handle/123456789/496131
標題: | A review on the association between glucagon-like peptide-1 receptor agonists and thyroid cancer | 作者: | WEI-YIH CHIU SHYANG-RONG SHIH CHIN-HSIAO TSENG |
公開日期: | 2012 | 卷: | 2012 | 起(迄)頁: | 924168 | 來源出版物: | Experimental Diabetes Research | 摘要: | There is a concern on the risk of thyroid cancer associated with glucagon-like peptide-1 (GLP-1) analogs including liraglutide and exenatide. In this article, we review related experimental studies, clinical trials and observational human studies currently available. In rodents, liraglutide activated the GLP-1 receptors on C-cells, causing an increased incidence of C-cell neoplasia. Animal experiments with monkeys demonstrated no increase in calcitonin release and no C-cell proliferation after long-term liraglutide administration. Longitudinal 2-year data from clinical trials do not support any significant risk for the activation or growth of C-cell cancer in humans in response to liraglutide. However, an analysis of the FDA adverse event reporting system database suggested an increased risk for thyroid cancer associated with exenatide after its marketing. Noticeably, a recent study discovered that GLP-1 receptor could also be expressed in human papillary thyroid carcinomas (PTC), but the impact of GLP-1 analogs on PTC is not known. Therefore, GLP-1 analogs might increase the risk of thyroid C-cell pathology in rodents, but its risk in humans awaits confirmation. Since GLP-1 receptor is also expressed in PTC besides C-cells, it is important to investigate the actions of GLP-1 on different subtypes of thyroid cancer in the future. Copyright ? 2012 Wei-Yih Chiu et al. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84862291156&doi=10.1155%2f2012%2f924168&partnerID=40&md5=379fa28a5d482c49dd78db828a44af91 https://scholars.lib.ntu.edu.tw/handle/123456789/496131 |
ISSN: | 1687-5214 | DOI: | 10.1155/2012/924168 | SDG/關鍵字: | calcitonin; cyclic AMP; exendin 4; glucagon; glucagon like peptide 1 receptor; liraglutide; mammalian target of rapamycin; messenger RNA; placebo; rosiglitazone; tetrahydrolipstatin; drug derivative; exendin 4; glucagon like peptide 1; glucagon like peptide receptor; glucagon receptor; glucagon-like peptide receptor; liraglutide; peptide; venom; calcitonin blood level; cancer growth; cell hyperplasia; cell proliferation; clinical trial (topic); diabetes mellitus; experimental study; food and drug administration; gene expression; human; immunoreactivity; in vitro study; neoplasm; nonhuman; obesity; observational study; phase 2 clinical trial (topic); phase 3 clinical trial (topic); primate; priority journal; protein expression; protein phosphorylation; review; RNA transcription; sensitivity and specificity; thyroid cancer; thyroid follicle cell; thyroid medullary carcinoma; tumor volume; animal; diabetes mellitus; disease model; drug potentiation; gene expression regulation; Macaca fascicularis; metabolism; mouse; rat; thyroid tumor; Animals; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Disease Models, Animal; Gene Expression Regulation; Glucagon-Like Peptide 1; Humans; Macaca fascicularis; Mice; Peptides; Rats; Receptors, Glucagon; Thyroid Neoplasms; Venoms |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。